| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | -0.084 | 0.02 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | 0.081 | 0.02 |
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | 0.63 | 0.02 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.082 | 0.02 |
| mRNA | ZM-447439 | GDSC1000 | pan-cancer | AAC | -0.087 | 0.02 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | -0.081 | 0.02 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.084 | 0.02 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | 0.083 | 0.02 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.02 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | 0.071 | 0.02 |